AZD7442 - a Potential Combination Therapy for the Prevention and Treatment of COVID-19

Participants randomized to AZD7442 will be administered dose 1, each in Cohort 1a (IM) and Cohort 1b (IV). Participants in Cohort 2 and 3 will receive AZD7442 (IV) doses 2 and 3, respectively. Participants in Cohort 4 will receive AZD7442 (IV) dose 4.

Participants randomised to placebo will receive the same volume of solution as participants on active treatment.